Retirement Systems of Alabama Has $136.62 Million Stake in Pfizer, Inc. (PFE)

Retirement Systems of Alabama decreased its position in Pfizer, Inc. (NYSE:PFE) by 4.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,067,379 shares of the biopharmaceutical company’s stock after selling 194,291 shares during the period. Pfizer comprises 0.7% of Retirement Systems of Alabama’s portfolio, making the stock its 22nd largest holding. Retirement Systems of Alabama owned 0.24% of Pfizer worth $136,623,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the company. Northstar Group Inc. boosted its holdings in shares of Pfizer by 0.4% in the second quarter. Northstar Group Inc. now owns 8,602 shares of the biopharmaceutical company’s stock valued at $289,000 after acquiring an additional 35 shares in the last quarter. River Wealth Advisors LLC boosted its holdings in shares of Pfizer by 0.3% in the second quarter. River Wealth Advisors LLC now owns 15,818 shares of the biopharmaceutical company’s stock valued at $531,000 after acquiring an additional 55 shares in the last quarter. Meridian Wealth Management LLC boosted its holdings in shares of Pfizer by 0.5% in the second quarter. Meridian Wealth Management LLC now owns 11,966 shares of the biopharmaceutical company’s stock valued at $402,000 after acquiring an additional 57 shares in the last quarter. Stone House Investment Management LLC boosted its holdings in shares of Pfizer by 0.9% in the first quarter. Stone House Investment Management LLC now owns 7,164 shares of the biopharmaceutical company’s stock valued at $245,000 after acquiring an additional 66 shares in the last quarter. Finally, Naples Global Advisors LLC boosted its holdings in shares of Pfizer by 0.3% in the first quarter. Naples Global Advisors LLC now owns 24,552 shares of the biopharmaceutical company’s stock valued at $840,000 after acquiring an additional 79 shares in the last quarter. 69.01% of the stock is currently owned by institutional investors and hedge funds.

Several brokerages have recently weighed in on PFE. Jefferies Group LLC set a $35.00 target price on shares of Pfizer and gave the company a “neutral” rating in a report on Wednesday, August 2nd. BMO Capital Markets set a $39.00 target price on shares of Pfizer and gave the company a “buy” rating in a report on Tuesday. Berenberg Bank set a $36.00 target price on shares of Pfizer and gave the company a “neutral” rating in a report on Tuesday. Zacks Investment Research raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $40.00 target price on the stock in a report on Tuesday, October 3rd. Finally, Cowen and Company set a $43.00 target price on shares of Pfizer and gave the company a “buy” rating in a report on Monday, August 14th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $38.32.

Pfizer, Inc. (NYSE PFE) opened at 35.06 on Wednesday. The firm’s 50-day moving average is $35.86 and its 200-day moving average is $33.92. The firm has a market cap of $208.51 billion, a PE ratio of 25.65 and a beta of 1.00. Pfizer, Inc. has a 12 month low of $29.83 and a 12 month high of $36.78.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Monday, October 30th. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.64 by $0.03. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The company had revenue of $13.17 billion during the quarter, compared to analyst estimates of $13.17 billion. During the same quarter last year, the firm posted $0.61 EPS. The business’s revenue for the quarter was up .9% on a year-over-year basis. Equities analysts expect that Pfizer, Inc. will post $2.56 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 1st. Stockholders of record on Friday, November 10th will be given a dividend of $0.32 per share. The ex-dividend date of this dividend is Thursday, November 9th. This represents a $1.28 annualized dividend and a dividend yield of 3.65%. Pfizer’s dividend payout ratio (DPR) is 94.12%.

COPYRIGHT VIOLATION NOTICE: This report was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another website, it was illegally stolen and republished in violation of international copyright laws. The correct version of this report can be read at https://www.com-unik.info/2017/11/01/retirement-systems-of-alabama-has-136-62-million-stake-in-pfizer-inc-pfe.html.

In other news, insider Alexander R. Mackenzie sold 7,350 shares of the firm’s stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $34.00, for a total transaction of $249,900.00. Following the completion of the transaction, the insider now owns 132,124 shares in the company, valued at approximately $4,492,216. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Alexander R. Mackenzie sold 15,000 shares of the firm’s stock in a transaction dated Monday, August 7th. The shares were sold at an average price of $33.50, for a total transaction of $502,500.00. Following the transaction, the insider now owns 151,474 shares of the company’s stock, valued at approximately $5,074,379. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 464,521 shares of company stock valued at $15,813,961. Insiders own 0.06% of the company’s stock.

Pfizer Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

What are top analysts saying about Pfizer Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pfizer Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit